HUE027223T2 - Új fenilamino-izonikotinamid vegyületek - Google Patents
Új fenilamino-izonikotinamid vegyületek Download PDFInfo
- Publication number
- HUE027223T2 HUE027223T2 HUE09790842A HUE09790842A HUE027223T2 HU E027223 T2 HUE027223 T2 HU E027223T2 HU E09790842 A HUE09790842 A HU E09790842A HU E09790842 A HUE09790842 A HU E09790842A HU E027223 T2 HUE027223 T2 HU E027223T2
- Authority
- HU
- Hungary
- Prior art keywords
- hydrogen
- hal
- cancer
- compounds
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (5)
- Szabadabb igénypontok 1. (ül képleté vegySletés ennek gyögyászaíítag elfogadható sés vagy sxolváljaí, a képletben R! jelentése hidrogén, snetil. etil, o-propil izopropil, SH vagy Hal, R" jelentése hidrogén, aaetoxi, etoxt, aceiMa, elásó, SH vagy Hal, Ry Kijelentése egymástól föggetlettdl hidrogén, SH vagy Hal közül vas kiválasztva, és Hal jelentése F, Cl, Bt vagy I.
- 2, Az l, igényponíszeriaJt vegyidet, amelyben a részletesebben meg nem jelölt ®^kók jelentése az· I igénypont szóróst! (11) képletben feltüntetett, de ahol az (IA s sdképloíbets R' jelentése Hal metU vagy etil, R* jelentése hidrogén. Hal, metoxi vagy acetilén, R" jelentése hidrogén vagy Hal, B"' jelentéve hidrogén vagy Hal, Mai jelentése f, Cl, Br vagy I, az (1.8) aiképletben E ! jelentése Hal, ÍV jelentése hidrogén vagy Hal, R? jelentése hidrogén vagy Hal, R'1 jelentése hidrogén vagy1 Hal, Hal jelentése F, Cl Br vagy I, a* HC.s tdképlethen R1 jelentése F, Cl, metis vagy etil. Kijelentése hidrogén, 1, Br, metoxi vagy acetilén, R" jelentése hidrogén vagy Hal, R* jelentése hidrogén vagy B&l Hal jelentése F, Cl, Br vagy !, az (ID) alképlaiben R{ jelentése P, Cl, tnetíl vagy etil. Kijelentése hidrogén,!, Bt, metoxi vagy acetilén, R'jelentése hidrogén vagy F, R* jelentése hidrogén vágj·' Cl as GB) alképletben R' jelentése F vagy CB R; jelentése I vagy fír, R" jelentése hidrogén vagy ÍR .^jelentése hidrogén vagy Cl ffit (IF) slképleiben Rl jelentése F vagy CB IC jelentése I vagy Br, R! jdentese hidrogén vagy F, R“ jelentése hidrogén vagy O, ax üG) aíkápfetben IC jelentése F vagy CL R* jelentése I vagy Br, R? jelentése hidrogén, R* jelentése hidrogén, és m (1H) alkéjtleihen R: jelentésé F, R* jelentése 1, R'! jelentése hidrogén vagy F, R* jelentése hidrogén vagy Cl* és enttek gyógysxérésaotiieg elfogadható sós vagy smlváljai.
- 3, Az 1. igénypont szerinti vágyóiét, amely vágyóiét a következőket hatalmasé csoportból van kiváláséi» va:¢$. SívííSk gyégysseréstsdleg elfogadható $-öi ss ssolvajai. 4. %ógys2«rkés24tmény, amely hatóanyagként agy» aa 1-3, ígéaypsöatök bármelyike aaeds«í \e&uu*ei vagy mmk gyégysaerésaetíleg elfogadható sóját vagy saalvátját íattahaa&sa gyógy&setésaeuleg elfogadható hordttóval együtt, 5, ás M Igénypontok Öárinélyte ááéthal #gytlet kagy :'Émk gy«gysse:résss?b®| :«ílbgSÉS^é shja vagy szolvátja jgyemként Ík5slmssiS:r&- 6, ás dk igénypernek bármelyike szerinti xegvüiet vagy essek gyogyazetészetiieg eiiogadhatsS sója vagy sroivsgs emlősök Μ1.ΊΚ. híperaktsvitSssai kapcsolatos Ihpetproiiterativ betegségeinek, vabssoint M8K kmetkád által medikák betegségbe ek kerdeaobeo történő mhalrommsm, ?, A 6. sgényptat: szenott vegyület vagy gyogysamkzetileg elfogadható sója vagy szolvátja a 6. igény-pere szerinti alkalmazásra, ahol a betegség rák, gyulladás, assay a: mirigy -gyűl 1 adás vagy vese betegsége fájáé,' lom, a kör jóindulata hiperpiázi&js, msztenózbk vaszkuiogeaézissel vagy analógé nótáméi kapcsolatos prosztata betegség, tumor angiogc-nézis, pikkelysömör, ekcéma és szkieroderma közöl kiválasztott bőrbetegségek, diabétesz, díahesikos mtinopdísa, korttszölört mi ampán a, életkorral OsszesÖggÖ oraktsta degeneráció, hemangiótna, giióma, melanóma és K&posí sx&dcóma csoportjáyild-áat.kivÉ&s^ya. í A ?.. IgépyponbszerlhSÍ vegyÜlétvagy gyögysKefészmilőg elfogadható sóm vagy szoivátja a ?. igény-pont szerinti alkalmazásra, ahol ti betegség rák,
- 9. Á S, igénypont szednií vegyidet vagy ennek gyógyszerészetiieg elfogadható sója vagy' sarc várja a 8. igénypont: szerinti alkalmazásra, ahol a rák agy, tüdő, pikkelyes sejt, hólyag, gyomor, hasnyálmirigy, emlő, fej, nyak, rendis, vese, petefészek, prosztata, vastag-végbéi, nyelőcső, itete. nőgyógyászati vagy rák, tneknőma, mieiogén leukemia, mielóma multiplex, krónikus mieiogén leukémia vagy mieloid sejtes leokényia,
- 10. Késziei (kit), amely kölön csontokban tartalmazza egy, az 1-3. Igénypontok közöl egy vagy több szerinti vegyüld vagy győjp^eí^tlki::«l%aáhatá''s^ kagy és egy további gyógyszerhatóanyag hatásos mennyiségét.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13785808P | 2008-08-04 | 2008-08-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE027223T2 true HUE027223T2 (hu) | 2016-08-29 |
Family
ID=41078311
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE09790842A HUE027223T2 (hu) | 2008-08-04 | 2009-07-27 | Új fenilamino-izonikotinamid vegyületek |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US8404725B2 (hu) |
| EP (1) | EP2307376B1 (hu) |
| JP (1) | JP2011529963A (hu) |
| KR (1) | KR101651700B1 (hu) |
| CN (1) | CN102099336B (hu) |
| AR (1) | AR072904A1 (hu) |
| AU (1) | AU2009279940B2 (hu) |
| BR (1) | BRPI0916566B8 (hu) |
| CA (1) | CA2732828C (hu) |
| CL (1) | CL2011000258A1 (hu) |
| CO (1) | CO6341612A2 (hu) |
| DK (1) | DK2307376T3 (hu) |
| EA (1) | EA018539B1 (hu) |
| EC (1) | ECSP11010867A (hu) |
| ES (1) | ES2560878T3 (hu) |
| HK (1) | HK1159097A1 (hu) |
| HR (1) | HRP20160044T1 (hu) |
| HU (1) | HUE027223T2 (hu) |
| IL (1) | IL210937A (hu) |
| MX (1) | MX2011001127A (hu) |
| MY (1) | MY151342A (hu) |
| NZ (1) | NZ591498A (hu) |
| PE (1) | PE20110665A1 (hu) |
| PL (1) | PL2307376T3 (hu) |
| PT (1) | PT2307376E (hu) |
| SI (1) | SI2307376T1 (hu) |
| UA (1) | UA107183C2 (hu) |
| WO (1) | WO2010017051A1 (hu) |
| ZA (1) | ZA201101661B (hu) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201201671A1 (ru) * | 2010-07-01 | 2013-08-30 | Мерк Патент Гмбх | Способ получения цис-1,2-диолов в килограммовом масштабе |
| EP2632899A1 (en) * | 2010-10-29 | 2013-09-04 | Bayer Intellectual Property GmbH | Substituted phenoxypyridines |
| HUE035751T2 (hu) | 2011-09-02 | 2018-08-28 | Novartis Ag | Gyulladásgátló szubsztituált ciklobuténdion vegyület kolinsó |
| WO2015018421A1 (en) | 2013-08-07 | 2015-02-12 | Rigshospitalet Copenhagen University Hospital | Antibodies, compounds and derivatives thereof for use in the treatment of male infertility |
| CN107108561B (zh) | 2014-11-20 | 2020-08-28 | 默克专利有限公司 | 用作irak抑制剂的杂芳基化合物及其用途 |
| WO2017033113A1 (en) | 2015-08-21 | 2017-03-02 | Acerta Pharma B.V. | Therapeutic combinations of a mek inhibitor and a btk inhibitor |
| CN106632021A (zh) * | 2016-09-27 | 2017-05-10 | 中国药科大学 | 2‑取代异烟酸类化合物、其制备方法及其用途 |
| AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| CN114761006A (zh) | 2019-11-08 | 2022-07-15 | Inserm(法国国家健康医学研究院) | 对激酶抑制剂产生耐药性的癌症的治疗方法 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| TW202342018A (zh) | 2022-03-04 | 2023-11-01 | 美商奇奈特生物製藥公司 | Mek激酶抑制劑 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5525625A (en) * | 1995-01-24 | 1996-06-11 | Warner-Lambert Company | 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| WO1999001426A1 (en) | 1997-07-01 | 1999-01-14 | Warner-Lambert Company | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as mek inhibitors |
| EP0993437B1 (en) | 1997-07-01 | 2006-11-08 | Warner-Lambert Company Llc | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors |
| CA2348236A1 (en) | 1999-01-13 | 2000-07-20 | Stephen Douglas Barrett | 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors |
| YU49401A (sh) | 1999-01-13 | 2004-07-15 | Warner-Lambert Company | Benzoheterocikli i njihova upotreba kao inhibitori mek |
| ATE311363T1 (de) | 1999-01-13 | 2005-12-15 | Warner Lambert Co | Sulfohydroxamsäure and sulfohydroxamate und ihre verwendung als mek-inhibitoren |
| ES2252996T3 (es) | 1999-01-13 | 2006-05-16 | Warner-Lambert Company Llc | Derivados de bencenosulfonamida y su uso como inhibidores de mek. |
| JP2002534446A (ja) | 1999-01-13 | 2002-10-15 | ワーナー−ランバート・カンパニー | ４′ヘテロアリールジアリールアミン |
| SK9822001A3 (en) | 1999-01-13 | 2002-08-06 | Warner Lambert Co | 1-heterocycle substituted diarylamines, pharmaceutical compositions based thereon and their use in therapy |
| GB9910577D0 (en) | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
| CA2403017A1 (en) | 2000-03-15 | 2001-09-20 | Warner-Lambert Company | 5-amide substituted diarylamines as mex inhibitors |
| GEP20053496B (en) | 2000-07-19 | 2005-04-25 | Warner Lambert Co | Oxygenated Esters of 4-Iodo Phenylamino Benzhydroxamic Acids |
| NZ535158A (en) | 2002-03-13 | 2007-06-29 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as MEK inhibitors |
| AU2003220202A1 (en) | 2002-03-13 | 2003-09-29 | Array Biopharma, Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
| GB0215823D0 (en) | 2002-07-09 | 2002-08-14 | Astrazeneca Ab | Quinazoline derivatives |
| US20050004186A1 (en) | 2002-12-20 | 2005-01-06 | Pfizer Inc | MEK inhibiting compounds |
| JP5214971B2 (ja) * | 2004-10-20 | 2013-06-19 | メルク セローノ ソシエテ アノニム | ３−アリルアミノピペリジン誘導体 |
| WO2007121269A2 (en) | 2006-04-11 | 2007-10-25 | Ardea Biosciences, Inc. | N-aryl-n'alkyl sulfamides as mek inhibitors |
| JP5269762B2 (ja) | 2006-04-18 | 2013-08-21 | アーディア・バイオサイエンシーズ・インコーポレイテッド | Ｍｅｋ阻害剤としてのピリドンスルホンアミドおよびピリドンスルファミド |
| CN101605540A (zh) | 2006-12-14 | 2009-12-16 | 埃克塞利希斯股份有限公司 | 使用mek抑制剂的方法 |
-
2009
- 2009-07-27 HU HUE09790842A patent/HUE027223T2/hu unknown
- 2009-07-27 NZ NZ591498A patent/NZ591498A/xx unknown
- 2009-07-27 US US13/057,052 patent/US8404725B2/en active Active
- 2009-07-27 AU AU2009279940A patent/AU2009279940B2/en active Active
- 2009-07-27 DK DK09790842.0T patent/DK2307376T3/en active
- 2009-07-27 CN CN200980128453XA patent/CN102099336B/zh active Active
- 2009-07-27 KR KR1020117005066A patent/KR101651700B1/ko active IP Right Grant
- 2009-07-27 PE PE2011000115A patent/PE20110665A1/es not_active Application Discontinuation
- 2009-07-27 CA CA2732828A patent/CA2732828C/en active Active
- 2009-07-27 WO PCT/US2009/051817 patent/WO2010017051A1/en active Application Filing
- 2009-07-27 PT PT97908420T patent/PT2307376E/pt unknown
- 2009-07-27 JP JP2011522112A patent/JP2011529963A/ja active Pending
- 2009-07-27 SI SI200931359T patent/SI2307376T1/sl unknown
- 2009-07-27 UA UAA201102396A patent/UA107183C2/ru unknown
- 2009-07-27 EA EA201100296A patent/EA018539B1/ru not_active IP Right Cessation
- 2009-07-27 EP EP09790842.0A patent/EP2307376B1/en active Active
- 2009-07-27 MX MX2011001127A patent/MX2011001127A/es active IP Right Grant
- 2009-07-27 MY MYPI20110408 patent/MY151342A/en unknown
- 2009-07-27 BR BRPI0916566A patent/BRPI0916566B8/pt active IP Right Grant
- 2009-07-27 ES ES09790842.0T patent/ES2560878T3/es active Active
- 2009-07-27 PL PL09790842T patent/PL2307376T3/pl unknown
- 2009-08-04 AR ARP090102980A patent/AR072904A1/es active IP Right Grant
-
2011
- 2011-01-27 IL IL210937A patent/IL210937A/en active IP Right Grant
- 2011-02-02 CO CO11011675A patent/CO6341612A2/es active IP Right Grant
- 2011-02-04 CL CL2011000258A patent/CL2011000258A1/es unknown
- 2011-03-03 EC EC2011010867A patent/ECSP11010867A/es unknown
- 2011-03-03 ZA ZA2011/01661A patent/ZA201101661B/en unknown
- 2011-12-14 HK HK11113513.8A patent/HK1159097A1/xx unknown
-
2013
- 2013-03-05 US US13/785,120 patent/US8889719B2/en active Active
-
2016
- 2016-01-14 HR HRP20160044TT patent/HRP20160044T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2307376B1 (en) | Novel phenylamino isonicotinamide compounds | |
| CA2582247C (en) | 3-arylamino pyridine derivatives | |
| US20070293544A1 (en) | Novel 4-Arylamino Pyridone Derivatives as Mek Inhibitors for the Treatment of Hyper-Proliferative Disorders | |
| JP5826972B2 (ja) | 酸セラミダーゼインヒビターおよびそれらの医薬としての使用 | |
| CN1139929A (zh) | 取代的3-亚芳基-7-氮杂羟吲哚化合物及其制备方法 | |
| TW201141480A (en) | Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof | |
| MX2011010065A (es) | Novedoso derivado de hidroxamato, un metodo de produccion del mismo y una composicion farmaceutica que comprende el mismo. | |
| CN108368060B (zh) | 一类嘧啶类衍生物激酶抑制剂 | |
| CN102639497A (zh) | 乳酸脱氢酶(ldh)的化合物抑制剂以及包含这些化合物的药学组合物 | |
| US20130102640A1 (en) | Method for the preparation of cis-1,2-diols in the kilogram scale | |
| CN118026880A (zh) | 芳基酰胺化合物、包含其的药物组合物及其用途 | |
| Deppe et al. | HAMILTON, BROOK, SMITH 4 REYNOLDS | |
| TW201908308A (zh) | 苯并咪唑類衍生物及其製備方法及其在醫藥上的用途 | |
| EP2955182A1 (en) | Pyridazinones for the treatment of cancer |